Mark De Rosch - Jan 19, 2023 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Role: Chief Operating Officer
Signature: /s/ Julie Feder, as Attorney-in-Fact
Stock symbol: AURA
Transactions as of: Jan 19, 2023
Transactions value $: $0
Form type: 4
Date filed: 1/23/2023, 05:36 PM
Previous filing: Nov 2, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AURA	Common Stock	Award	$0	+42.3K	+257.86%	$0.00	58.6K	Jan 19, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AURA	Stock Option (Right to Buy)	Award		+65K			65K	Jan 19, 2023	Common Stock	65K	$10.18	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant.
F2	The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments.